Zacros T-TAS BAPA tube on a blue backgrund

BAPA Anticoagulant Blood Collection Tube

$0.00

  • Catalog #: 18004
  • Method: Anticoagulant
  • Packaging: Box/50x3ml tubes
  • Type: Blood Collection
  • Use: In Vitro Diagnostic (IVD)

Benzylsulfonyl-D-Arg-Pro-4-amidinobenzylamide (BAPA) is a strong, synthetic anticoagulant that inhibits both Factor Xa and thrombin (Factor IIa), blocking the coagulation cascade allowing collecting blood to remain in the liquid state.

The BAPA does not interfere with the physiologic levels or action of calcium.

Features

  • BAPA is a strong, synthetic dual inhibitor of coagulation
  • Does not interfere with physiologic levels of calcium ions
  • 3 mL blood draw

Each box contains 50 blood collection tubes intended for use wtih the PL Chip on the T-TAS 01.

Each vacuum sealed blood vial is intended to anticoagulate 3 mL of whole blood.

Publications

  1. Tauer JT, Lohse J, König S, Knöfler R. Investigations of Platelet Function in Whole Blood with BAPA as Anticoagulant. Transfus Med Hemother. 2010;37(5):284-288. doi:10.1159/000320361
  2. Mani H, Hellis M, Lindhoff-Last E. Platelet function testing in hirudin and BAPA anticoagulated blood. Clin Chem Lab Med. 2011;49(3):501-507. doi:10.1515/CCLM.2011.074
  3. Kaiser AF, Neubauer H, Franken CC, Krüger JC, Mügge A, Meves SH. Which is the best anticoagulant for whole blood aggregometry platelet function testing? Comparison of six anticoagulants and diverse storage conditions. Platelets. 2012;23(5):359-367. doi:10.3109/09537104.2011.624211
  4. Hellstern P, Stürzebecher U, Wuchold B, et al. Preservation of in vitro function of platelets stored in the presence of a synthetic dual inhibitor of factor Xa and thrombin. J Thromb Haemost. 2007;5(10):2119-2126. doi:10.1111/j.1538-7836.2007.02716.x
  5. Kaiser AF, Endres HG, Mügge A, Neubauer H. BAPA, a synthetic dual inhibitor of Factor Xa and Thrombin, extends the storage-time to a maximum of 12 hours in ADP- and 24 hours in arachidonic acid-induced impedance aggregometry. Scand J Clin Lab Invest. 2011;71(3):253-256. doi:10.3109/00365513.2011.559554